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Purinergic receptors are attractive therapeutic targets that can regulate 
several facets of the immune system. This dissertation examines the role of 
purinergic G protein-coupled Adenosine 2a (A2aR) receptors in regulating 
adaptive immune responses during the primary response to vaccination and during 
self-antigen recognition in the context autoimmunity. Administration of A2aR 
agonist CGS-21680 (CGS) can alter CD4 T cell differentiation by diverting helper 
T cells away from a germinal center follicular helper T cells (GC-Tfh) linage that 
promotes the survival, differentiation, isotype class-switching, and affinity 
maturation of B cells. Although GC-Tfh cells are beneficial during the clearance 
of certain pathogens, they also can be detrimental if they malfunction and 
mistakenly provide help to pathogenic self-specific B cells. Previous studies 
suggest that A2aRs acts as a barrier to autoimmunity by limiting inflammatory 
responses. Our studies support this claim by showing that prophylactic treatment 
with CGS blocks autoimmune arthritis. A2aR agonist treatment caused a 
reduction in the frequency and number of pathogenic GC-Tfh cells and isotype 
class-switched plasmablasts that respond to autoantigen. CGS treatment of mice 
after the early onset of mild arthritis also had a therapeutic benefit and blocked 
disease progression. CGS therapy reduced the number pathogenic GC-Tfh cells 
and autoantibody titers, suggesting that A2aR downstream signals may serve to 
limit dangerous GC-Tfh cell effectors that contribute to autoimmune disease 
manifestations, thus making it an attractive target for future immunotherapies. 
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1.1 Purinergic receptors 
Adenosine-5'-triphosphate (ATP) is multifaceted nucleoside that regulates 
several biological functions including immunoregulation (1,2). Under steady state 
conditions the concentration gradient of ATP is relatively higher in the cell 
cytoplasm versus the extracellular space. However, under stressful conditions 
(infection, tissue damage, or sterile inflammation) the extracellular milieu shifts 
toward a higher ATP concentration (2). ATP can be released from cell-membrane 
channels such as pannexins, connexins, maxi channels and P2X7R pores (3). 
Extracellular ATP (eATP) is considered a danger-associated-molecular pattern 
that can activate both innate and adaptive immune responses (3). Most immune 
cells express ATP specific inotropic receptors P2XRs that can promote the 
activation of monocytes, macrophages, dendritic cells, T cells, Regulatory T cells 
(Tregs), and invariant natural killer T (iNKT) cells (4). P2XRs can also elicit 
cytokine release of innate immune cells and IgE shedding by B cells (4).  
The immunoreactive effects of eATP can be counter-regulated by 
ectoenzymes CD39 (ENTPD1) and CD73 (ecto-5’-nucleotidase) that sequentially 
hydrolyze ATP to AMP (adenosine 5’-monophosphate) by CD39 and AMP to 
extracellular adenosine by CD73 (5,6,2). Adenosine is considered an 
immunosuppressive purine nucleoside that governs several inflammatory 
responses via four different G protein–coupled adenosine receptors (A1, A2a, 
A2b, A3) (7,8). Adenosine A2a receptors (A2aRs) are expressed primarily on 
cells of hematopoietic origin, particularly on activated cytotoxic CD8 and helper 
CD4 T cells (9–11). Studies using mouse models of T cell–mediated autoimmune 
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disorders (12, 13) as well as graft-versus-host disease (14) have shown that A2aR 
signaling can restore immune homeostasis by promoting the induction of T cell 
anergy, regulatory T cell (Treg) differentiation, and suppression of effector T cell 
functions. 
 
1.2 Immunomodulatory effects of A2aR signals 
A. Anergy 
Anergy is a mechanism of peripheral immune tolerance that drives 
potentially dangerous T cells toward a state of functional unresponsiveness that is 
characterized by defective IL-2 production, inhibited cell cycle progression, and 
obstructed effector/memory T cell differentiation (15). Previous studies report that 
endogenous adenosine and selective A2aR agonists can inhibit dangerous effector 
responses to self-antigen by promoting a state of functional unresponsiveness in 
autoreactive self-specific T cells (12). Powell and colleagues offered a 
mechanistic explanation of how A2aR signals promote anergy by inhibiting IL-2 
production (18). A2aR activation enhances intrinsic levels of cAMP (Cyclic 
adenosine monophosphate), a second messenger that can bind to and activate 
downstream molecules such as the cAMP-dependent kinase, protein kinase A 
(PKA).  Enzymatically activate PKA phosphorylates transcription factors like 
cAMP responsive element-binding protein (CREB) that sit either in proximity or 
directly on the promoter regions that drive the transcription of A2aR-regulated 
genes (16, 17) (Fig. 1). Phosphorylation of CREB (p-CREB) at the conserved 
serine residue 133 can promote the recruitment of the transcriptional co-activator 
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cAMP-responsive element modulator (CREMa) (17-19). CREB and CREMa can 
form a heterodimer complex that binds upstream of the IL-2 promoter-enhancer 
site and suppress the production of IL-2 (18). Therefore, it is possible that A2aR 
promotes T cell anergy by reducing IL-2.  
 
B.  Regulatory T cells 
Regulatory T cells (Tregs) have a high co-expression of cell-surface 
ectoenzymes CD39 and CD73 that breakdown extracellular ATP to adenosine 
(Fig. 2)(49). Extracellular adenosine can enhance the immunoregulatory activity 
of Tregs by activating A2a receptor (A2aR) signals that enhance their suppressive 
functions (12, 49, 50). Studies using mouse models of colitis and graft versus host 
disease have shown diminished protection in mice with A2aR-deficient Tregs 
(13,51) (Fig. 2).  Ohta et al. (52) reported that in addition to enhancing Treg 
suppression, A2aR signals can also enhance the proliferation of natural Tregs and 
promote the induction of new Treg (Fig. 2). A study by Zarek et al. supports these 
observations by reporting enhanced Foxp3 and LAG3 mRNA levels in T cells 
activated in the presence of a selective A2aR agonist (12). A2aR activation can 
also enhance the production of TGF-b, an essential molecule for the induction of 
Tregs (12). Therefore, it is possible that adenosine promotes T cell tolerance by 
activating A2aR signals that enhance the performance of Tregs and increase the 





C. Effector T cells 
A2aRs negatively regulate adaptive immune responses by inhibiting the 
effector functions of lymphocytes (2,7). Loss of A2aR signaling in Adora2a-
deficient (A2aR KO) mice leads to enhanced control of tumor growth by CD8 T 
cells (20). An investigation of tumor Ag–specific CD8 polyclonal T cells in A2aR 
KO mice revealed that endogenous adenosine limits their clonal expansion and 
effector functions needed to effectively eradicate tumors (20).  In vitro polarizing 
assays suggest that A2aR signaling alters CD4 T cell differentiation by inhibiting 
the induction of Th1 (Tbet+), Th2 (GATA3+), and Th17 (RORgt+) effector T cell 
phenotypes (21, 22). In vivo, activation of A2aRs during acute infection with 
Toxoplasma gondii reduced the number of Th1 IFN-g–producing CD4 T cells 
(24). In a mouse model of asthma, selective A2aR agonists also reduced the 
expression of RORgt, the master regulator of Th17 cells, in the lung tissue of 
affected mice (23). This matched the reduced production levels of IL-17 in 
affected mice (23). Models of colitis, graft-versus-host disease (GVHD), and 
autoimmunity also observed enhanced survival due to a decrease production of 
IL6, TNFa and IFNγ suggesting that A2aR signaling can reduce Th1 and Th17 
responses (4). However, until very recently no studies had indicated a role for 
A2aR signaling in Tfh differentiation despite the role of other purinergic receptors 
such as P2X7 in regulating Tfh homeostasis (25). It is possible that A2aR-
mediated effects on Tfh cells may have been overlooked due to a requirement of 
Ag specificity between T cells and B cells during Tfh differentiation (26). 
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C. Humoral immune responses during hypoxia 
Abbott and colleagues reported that the germinal center (GC), where B 
cells undergo class-switch recombination, somatic hypermutation, and clonal 
selection, develop an oxygen-low hypoxic microenvironment (53). Hypoxia 
creates an extracellular adenosine rich environment by releasing extracellular 
adenine nucleotides ATP and AMP into the extracellular matrix that can be 
broken down to adenosine by purinergic receptors CD73 and CD39 (54). 
Interestingly, hypoxia-inducible factor-1a (HIF-1a) can promote the transcription 
of CD73 and CD39 (55). Metabolically stressed cells from hypoxic conditions can 
also release extracellular adenosine via nucleoside transporters (56). However, 
excess extracellular adenosine is quickly eliminated by mechanisms that regulate 
extracellular adenosine levels by promoting the uptake of adenosine or by 
enhancing the cell surface expression of adenosine deaminase (ADA), a molecule 
that break adenosine to inosine (57, 58).  Hypoxic environments can diminish the 
enzymatic activity of both adenosine kinases and ADA, therefore hypoxia not 
only promotes the production of extracellular adenosine, but also inhibits the 
mechanisms that clear excess extracellular adenosine. HIF-1a can also enhance 
the transcription of A2a and A2b receptors (59), therefore it is plausible that 
adenosine may be acting on a variety of immune cells in a hypoxic germinal 
center that regulates antibody mediated immune responses. 
 
1.3 Germinal Center Follicular Helper T cell differentiation and function 
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Follicular helper (Tfh) differentiation involves the interplay of T cell 
intrinsic and extrinsic factors that push an uncommitted CD4 T cell progenitor 
toward a Tfh lineage (26). T cell extrinsic signals are exchanged between CD4 T 
cells and dendritic cells (DCs) through costimulatory receptor/ligand interactions 
such as CD28/(CD80/CD86) and inducible T cell costimulator (ICOS)/ICOS 
ligand (26,28). Cross talk between T cells and DCs can also occur through the 
secretion and recognition of effector cytokines like IL-6 and IL-21(26). These T 
cell extrinsic signals work in synergy to initiate the transcription of Tfh promoting 
factors such as B-cell lymphoma 6 protein (Bcl-6) (29, 30, 31), Maf (26, 27, 31), 
and signal transducer and activator of transcription 3 (STAT3) (26, 27, 31) while 
at the same time suppressing Tfh repressing factors such as PR domain zinc finger 
protein 1 (BLIMP-1) (29, 32, 33), forkhead box proteins FoxP1 (33, 34), 
Foxo1(35, 33) and STAT5 (31, 33). Tfh differentiation also requires the 
expression of chemokine receptor 5 (CXCR5) that allows CD4 T cells to migrate 
toward the B cell follicle (26). At the B cell follicles, CD4 T cell progenitors 
exchange signals with B cell that allow them to enter the specialized lymphatic 
structure known as a germinal center (GC) (30, 37). Once in the GC, CD4 T cell 
progenitors take on a GC-Tfh phenotype by expressing effector molecules like 
CD40L (31, 37) as well as signaling lymphocytic activation molecule (SLAM) 
associated receptors (29, 32) and programed cell death (PD-1) receptor (29,36). 
Furthermore, GC-Tfh cells also secrete effector cytokines such as IL-21 and IL-4 
that promote the propagation and class-switching of B cells (38). 
1.4 Discussion  
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Helper CD4 T cells are critical regulators of adaptive and innate immune 
responses. Their absence is drastically emphasized in patients with acquired 
immune deficiency syndrome (AIDS) or severe combined immunodeficiency 
(SCID) who are unable to clear infections caused by otherwise harmless 
microbes. CD4 T cells carry out a broad-spectrum of effector functions uniquely 
suited to eliminate specific pathogens by activating macrophages, cytotoxic T 
CD8 cells, and B cells. Identifying the factors that fine-tune CD4 T cell responses 
may be instrumental in the development of immune-targeted therapies and new 
vaccine approaches.   
Although CD4 T cells are essential for immune homeostasis, they can at 
times malfunction, confuse self-antigens for foreign invaders, and mount 
inappropriate responses against self-tissues. Enhanced frequencies of GC-Tfh 
cells have been reported in patients suffering from antibody-mediated 
autoimmune disorders such as Rheumatoid Arthritis (RA) and systemic lupus 
erythematosus (SLE) (43,45). Multiple studies have shown a tight correlation 
between the frequency of GC-Tfh cells and the onset of disease (44).  
Autoimmune disorders affect approximately 50 million Americans and are 
among the top 10 causes of death for women under the age of 65 (47). While 
many therapies are effective at alleviating pain and inflammation, most are not 
curative and do little to stop or reverse disease progression (47). Understanding 
the mechanisms that drive and sustain tolerance in healthy individuals may unlock 
the key to curative therapies that may go beyond pain alleviation and restore 
immune homeostasis.  
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The therapeutic benefits of adenosine in autoimmune disorders have been 
previously reported in patients treated with methotrexate (48) and sulfasalazine 
(60), popular disease-modifying antirheumatic drugs (DMARD) commonly 
prescribed to individuals suffering from systemic autoimmune disorders like RA. 
The anti-inflammatory effects of methotrexate and sulfasalazine are attributed to 
augmented levels of extracellular adenosine (60). Therefore, identifying the 
factors downstream of adenosine that alleviate symptoms of arthritis may create a 
unique opportunity to generate more effective next-generation immune targeted 
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Adenosine A2a receptor (A2aR) signaling acts as a barrier to 
autoimmunity by promoting anergy, inducing regulatory T cells, and inhibiting 
effector T cells. However, in vivo effects of A2aR signaling on polyclonal CD4 T 
cells during a primary response to foreign antigen (Ag) has yet to be determined. 
To investigate the in vivo effects of A2aR signaling on naïve polyclonal CD4 T 
cells during a primary response to foreign Ag we used a vaccination approach that 
allowed us to track Ag-specific CD4 T cells that differentiate into various T cell 
lineages such as Th1, Th17, Tregs, and T follicular helper (Tfh) cells. No reports 
to date have indicated a role for A2aR signaling in Tfh differentiation despite the 
role of other purinergic receptors such as P2X7 in regulating Tfh homeostasis 
(25). It is possible that A2aR-mediated effects on Tfh cells may have been 
overlooked due to a requirement of Ag specificity between T cells and B cells 
during Tfh differentiation (26). 
 To address this, we used a vaccine that consists of 2W1S peptide 
covalently coupled to PE (61). This allowed us to look at the interplay between 
endogenous Ag-specific 2W1S: I-Ab-specific T cells and PE-specific B cells (61). 
We initially sought to characterize polyclonal Ag-specific CD4 T cell anergy 
induction and Treg generation during A2aR signaling by tracking of 2W1S: I-Ab 
tetramer-binding T cells in mice treated with the selective A2aR agonist CGS-
21680 (CGS). We discovered that CGS has no impact on the Ag-induced clonal 
expansion of polyclonal 2W1S-specific CD4 T cells, nor does it promote the 
induction of anergy or Treg differentiation in our vaccination system. CGS did 
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not appear to reduce Th1 or Th17 differentiation; instead, A2aR signaling directly 
inhibited 2W1S: I-Ab-driven CD4 T cell differentiation toward the germinal 
center (GC)-Tfh fate, and reduced cognate GC B cell responses. Therefore, this 
work identifies a novel A2aR-mediated control mechanism during vaccination 
that regulates CD4 T cell differentiation and function 
 
2.2 Activation of A2a receptors during the primary response to vaccination fails 
to induce anergy or promote the differentiation of Tregs 
The activation of A2aRs in many biological systems is associated with the 
production of intracellular cAMP, a second-messenger known for its anti-
proliferative function (62). To investigate the effects of A2aR signaling during the 
primary CD4 T cell response to antigen, we used a tetramer of the major 
histocompatibility complex II I-Ab molecule containing the 2W1S peptide to 
study the in vivo proliferation and differentiation of polyclonal 2W1S: I-Ab-
specific CD4 T cells following immunization with a 2W1S peptide coupled to PE 
in CFA. This vaccination approach induces 2W1S: I-Ab-specific CD4 T cells to 
undergo clonal expansion and differentiation to Th1, Th17, Tregs, and Tfh 
lineages (61). Coupling 2W1S and PE together also allows for the interplay 
between 2W1S-specific GC-Tfh cells and PE-reactive GC B cell. This occurs 
when PE-specific B cells internalize 2W1S-PE through BCR recognition of PE 
resulting in the display 2W1S: I-Ab complexes, and allows them to exchange 
helper signals with 2W1S: I-Ab–specific CD4 T cells (61). The effects of A2aR 
activation were tested by treating immunized mice twice daily with the selective 
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A2aR agonist CGS (2.5 mg/kg i.p.) or vehicle alone as a control (PBS) (12). As 
shown in figure 3A, the clonal expansion of the 2W1S: I-Ab-specific polyclonal 
CD4 T cell population as a whole was no different in CGS- or PBS-treated mice. 
Consistent with preserved clonal expansion, we also observed no increase in the 
number of 2W1S: I-Ab-specific Foxp3+ Tregs during this immunization in the 
presence of CGS (Fig. 3B).  Therefore, A2aR signaling did not inhibit clonal 
expansion nor did it enhance Treg cell differentiation after vaccination with 
antigen in CFA. 
We next examined the capacity of A2aR signaling to promote anergy in 
2W1S: I-Ab-specific polyclonal CD4 T cells during vaccination. To test the 
effects of A2aR signaling on the development of anergy, we examined two 
surface molecules whose high gene expression marks functionally unresponsive 
anergic T cells: CD73 (Nt5e) and FR4 (Izumo1r) (63, 64). Remarkably, CGS 
treatment led to a reduction rather than rise in the number of 2W1S-specific CD4 
T cells that expressed high levels of these two anergy markers (Fig. 3C). Also 
consistent with an inability to promote tolerance in this system, CGS treatment 
led to an increase in the fraction of 2W1S: I-Ab-specific CD4 T cells that 
continued to express high levels of the proliferative marker Ki67 at day 7 (Fig. 
3D). Taken together, these data indicated that A2aR signaling cannot inhibit the 
proliferation of polyclonal antigen-specific CD4 T cells during antigen priming in 




2.3 Activation of adenosine A2a receptors interferes with the differentiation of 
Tfh and GC-Tfh cells during antigen priming 
Paradoxically, primed CD4 T cells in CGS-treated mice expressed even 
lower levels of the anergy markers CD73 and FR4 than mice exposed to vehicle 
alone (Fig. 3C). Previous studies have demonstrated moderate levels of FR4 and 
CD73 expressed on Tfh cells (65). Although the role of these two molecules in 
Tfh generation and function remains unknown, this observation led us to the 
hypothesis that A2aR signaling interferes with Tfh differentiation. Mice primed 
with 2W1S in CFA did develop a large population of CXCR5+ 2W1S: I-Ab-
specific CD4 T cells that expressed moderate levels of FR4 and CD73 (Fig. 2 A, 
B). In contrast, treatment of primed mice with CGS led to a loss in the generation 
of this FR4int CD73int CXCR5+ 2W1S: I-Ab-specific CD4 T cell subset. 
To more formally assess A2aR-regulated Tfh differentiation, we 
investigated the expression of the cell surface marker PD-1 and the transcription 
factor Bcl6 in primed 2W1S: I-Ab-specific CD4 T cells (31, 32). CD4 T cells that 
express the highest levels of CXCR5, Bcl6, and PD-1 have been characterized as 
GC-Tfh cells (Bcl6hi CXCR5hi) and are known to provide cognate help to antigen-
specific B cells within germinal centers, whereas CD4 T cells expressing lower 
levels are characterized as Tfh cells (Bcl6lo CXCR5lo) and reside at the T cell/B 
cell border (66). During primary immunization, CGS treatment reduced both the 
frequency and number of 2W1S: I-Ab-specific Tfh and GC-Tfh cells (Fig. 4 C-E).  
Consistent with a shift toward alternate differentiation fates, CGS treatment also 
elicited a small but significant increase in the number of 2W1S: I-Ab-specific non-
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Tfh cells. Therefore, our experiments revealed a novel role for A2aR pathway 
activation in the inhibition of Tfh and GC-Tfh cell differentiation.  
 
2.4 A2aR inhibition of Tfh differentiation is T cell intrinsic 
Although A2aR expression is known to be highly induced on CD4 T cells 
following TCR ligation (9-11), the expression of this adenosine receptor might 
also be expected on other cells of hematopoietic origin.  Additionally, Tfh cell 
differentiation is a multifactorial process whose regulation likely involves 
multiple additional cell types, particularly dendritic cells and B cells (31, 32, 66). 
Therefore, it was important to determine whether the effects of CGS were the 
result of direct A2aR engagement on the 2W1S: I-Ab-specific CD4 T cells. To 
address this question, CD4-Cre Adora2af/f conditional knock-out (KO) mice 
lacking A2aRs only on their T cells were immunized with 2W1S-PE and 
compared to wildtype (WT) A2aR-expressing littermates following a 7d course of 
CGS treatment. In the absence of T cell-expressed A2a receptors, CGS treatment 
lost its capacity to reduce Bcl6 expression and block 2W1S: I-Ab-specific GC-Tfh 
differentiation, and its inhibitory effects on Tfh cells appeared greatly blunted 
(Fig. 5 A, B).  Likewise, treatment of CD4-Cre Adora2af/f mice with CGS failed 
to induce an increase in non-Tfh cells during 2W1S antigen priming.  Given that 
Bcl6 promotes differentiation to the Tfh and GC-Tfh fates in part by repressing 
other lineage-specific transcription factors such as Tbet and RORgt (31, 32, 66), 
we further assessed these non-Tfh cells. WT mice significantly increased the 
frequency and number of 2W1S: I-Ab-specific RORgt + Th17 cells when their 
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A2aRs were directly bound by the adenosine agonist, whereas Tbet+ Th1 and 
Foxp3+ Treg differentiation appeared not to be regulated by A2aR signaling (Fig. 
5 C-E).  A small, but statistically insignificant increase in RORgt + Th17 cells was 
also observed in KO mice treated with CGS (Fig. 5 C-E). Thus, direct CD4 T cell 
A2aR signaling shifts the balance of differentiation away from the GC-Tfh fate 
toward Th17 effector cell generation during the primary response to antigen. 
 
2.5 T cell-intrinsic A2aR activation reduces T-dependent B cell immunity 
GC-Tfh cells promote the survival, differentiation, isotype class switch, 
and affinity maturation of antigen-specific B cells in germinal centers (66). 
Therefore, we hypothesized that A2aR signaling in T cells during primary 
immunization would interfere with the T-dependent B cell response to 
vaccination. To test this, WT and CD4-Cre Adora2af/f mice (KO) mice were 
immunized with a protein complex containing 2W1S coupled to PE (2W1S-PE) 
either with or without CGS treatment, and then PE-specific B cells were enriched 
using magnetic beads and characterized by flow cytometry. An ~50-fold 
expansion of PE-specific B cells was seen in WT and KO PBS-treated mice 
following immunization, as compared to naïve mice (Fig. 6 A-C). Consistent with 
the hypothesis, the number of PE-specific B cells found after vaccination was 
significantly reduced in CGS-treated WT hosts, but not in mice whose CD4 T 
cells lacked A2aRs. CGS treatment appeared to have its greatest inhibitory effect 
on the frequency and number of GC-phenotype CD38– GL7+ PE-binding B cells 
in the WT mice, although all B cell subpopulations were affected (Fig. 6 A-D). 
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Importantly, these inhibitory effects of CGS on PE-specific B cells during 
immunization were blunted in mice that lacked Adora2a gene expression 
specifically within the T cell compartment. Therefore, these data suggest that the 
loss of antigen-specific GC-Tfh differentiation that occurs during strong A2aR 
signaling on CD4 T cells is sufficient to abrogate the provision of cognate T cell 
help to GC B cells during their primary response to antigen.  
 
2.6 A2aR signals reduce the number of germinal centers 
WT and KO hosts were immunized with 2W1S-PE and treated with PBS 
or CGS. Tissue slides of whole spleen images were collected and germinal centers 
were addressed by staining for GL7, IgD, B220, and Dapi. GL7+B220+Dapi+IgD- 
germinal centers were manually quantified (Fig. 7A). The frequency of the 
germinal centers was elevated in both WT and KO immunized mice compared 
with unimmunized controls (Fig. 7B). CGS treatment in WT immunized mice 
reduced the frequency of germinal centers compared to PBS treated WT 
immunized mice (Fig. 7B). This matches our flow cytometry data where we 
observed a lower frequency of GC-Tfh and GC- B cells in WT mice treated with 
CGS. The frequency of germinal centers in KO immunized mice treated with 
CGS was comparable to PBS treated WT and KO groups (Fig. 7B). This also 
matched our flow cytometry observations and suggested that A2aR disruption of 
germinal centers is T-cell dependent. In addition, we also zoomed in on specific 
germinal centers and saw that the few germinal centers found in unimmunized 
mice appeared smaller in size compared to immunized WT and KO mice. Agonist 
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treatment seems to slightly decrease the GC size in WT mice; however, the size of 
the GCs in KO mice treated with CGS appears comparable to KO PBS treated. 
mice (data not shown). 
 
2.7 Discussion 
The identification of novel signaling elements that fine-tune CD4 T cell 
lineage differentiation during primary immunization offers new opportunities to 
improve the efficacy of vaccines and targeted immunotherapies (36, 67, 68). Our 
data suggest that in vivo A2aR signaling during the primary response to antigen 
plus a strong adjuvant diverts CD4 T helper cells away from the Tfh and GC-Tfh 
lineages. Given the key role of alternative T differentiation fates such as Th17 in 
protection against mucosal barrier infections (36), it is conceivable that selective 
A2aR agonists could be useful during vaccination to shape an optimal T 
differentiation response against pathogens. 
A2aRs also appear to be a particularly attractive therapeutic target for the 
treatment of B cell-dependent autoimmune disorders such as systemic lupus 
erythematosus (45,69) and rheumatoid arthritis (RA) (43,44). Indeed, previous 
studies have shown a positive correlation between the number of Tfh cells and 
disease burden in patients with RA (43,44). Perhaps consistent with this, A2aR 
agonists effectively suppress animal models of inflammatory arthritis (70). The 
fact that the first-line anti-rheumatic drugs methotrexate and sulfasalazine act, in 
part, through the generation of extracellular adenosine and A2aR signaling (60), 
lends further support to the notion that A2aR signaling can ameliorate T-
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dependent B cell autoreactivity.  
It should be noted that the ablation of A2aRs in these vaccination 
experiments using conditional knock-out mice failed to significantly enhance 
antigen-specific Tfh or GC-Tfh differentiation. Similarly, use of a selective 
antagonist of A2aRs during immunization did not reliably alter CD4 T cell 
differentiation (data not shown). Although strong A2aR signaling with an agonist 
can be inhibitory for Tfh and GC-Tfh differentiation in normal CD4 T cells, under 
normal circumstances endogenous extracellular adenosine may play no role in 
CD4 T cell fate selection within secondary lymphoid organs following i.p. 
immunization in adjuvant. Alternatively, unspecified factors (e.g., increased 
A2bRs, decreased adenosine kinase) may compensate for the loss of A2aRs in 
KO mice. Activated T cells are known to upregulate adenosine deaminase (ADA), 
an enzyme capable of metabolizing adenosine to inosine (70). Therefore, strong 
continuous A2aR signaling from endogenous adenosine sources may only occur 
under special circumstances such as hypoxia where CD73 is up-regulated to 
facilitate increased extracellular adenosine production in close proximity to A2a 
receptors (59, 72).  Going forward, it will be important to identify the 
immunological context (spatial and temporal) whereby extracellular adenosine 






3.8 Materials and Methods: 
Mice 
B6 (WT) mice were purchased from Charles River Breeding Laboratories 
under a contract from the National Cancer Institute (Frederick, MD). Adora2af/f 
mice containing loxP sites on either side of exon 2 of the Adora2a gene (a gift 
from Joel Linden, La Jolla Institute for Allergy and Immunology, La Jolla, CA) 
(11) were crossed with CD4-Cre mice (a gift from Michael Farrar, University of 
Minnesota, Minneapolis, MN) to generate conditional A2aR T cell knockout 
(KO) mice. Non-Cre littermates were used as WT controls. Mice were bred and 
housed in specific-pathogen free conditions in animal facilities at the University 
of Minnesota, Twin Cities. All experimental protocols were performed in 
accordance with guidelines of the University of Minnesota Institutional Animal 
Care and Use Committee and the National Institutes of Health. 
 
Immunization and selective A2aR agonist treatment 
Mice were given an intraperitoneal (i.p.) vaccine containing 200 µl of 0.6 
µg of 2W1S peptide conjugated to 25 µg of PE emulsified in Complete Freund’s 
Adjuvant (CFA) (Sigma-Aldrich) as previously described (61). Mice were then 
given a 7d course of twice daily i.p. injection with the selective A2aR agonist, 





Cell enrichment and flow cytometry 
Lymph nodes (LN) and spleens were collected and divided for separate 
enrichments of 2W1S:I-Ab tetramer-specific CD4 T cells and PE-specific B cells. 
2W1S:I-Ab APC-labeled tetramers were used to stain and enrich for 2W1S-
specific CD4 T cells (61). PE B cell enrichment was performed by mixing cell 
suspensions with 1 µg of PE (ProZyme) (61). Isolation of PE-specific B cells and 
for 2W1S: I-Ab-specific CD4 T cells was done using magnetic beads (STEM cell 
Technologies) (61). Enriched 2W1S T cells were first surface stained with 
CXCR5 (2G8), PD-1 (J43), CD4 (RM4-5), CD44 (IM7), as well as with the 
irrelevant cell exclusion antibodies CD11c (N418), B220 (RA3-6B2), CD8 (53-
6.7), and F4/80(BM8), and then fixed/permeabilized using a 
fixation/permeabilization kit (eBioscience) followed by intracellular staining with 
Foxp3 (FJK-16s), Tbet (4B10), Bcl6 (K112-91), RORg (Q31-378), and Ki67 
(SoA15). Enriched PE-specific B cells were surface stained with B220 (RA3-
6B2), GL7 (GL-7), CD38 (90), IgM (RMM-1), and IgD (11-26c.2a), as well as 
with the irrelevant cell exclusion antibodies CD11c (N418), CD4 (GK1.5), CD8 
(53-6.7), and F4/80(BM8), and then they were fixed/permeabilized using a 
fixation/permeabilization kit (eBioscience) and intracellular stained with goat 
anti-mouse Ig (H+L) (A11068). Anergy in 2W1S:I-Ab-specific CD4 T cells T 
cells was assessed by staining with CD73 (TY11.8) and folate receptor 4 (FR4, 
12A5) as previously outlined (63, 64). Cells were analyzed on a Fortessa (Becton 




Spleens from WT and KO hosts immunized with 2W1S-PE and treated 
with PBS or CGS were frozen in a Tissue-Tek compound using a liquid nitrogen-
cooled bath of 2-methylbutane. 7-um sections were cut using a Leica CM1860 
UV cryostat, air dried for at least 30 minutes, fixed in ice-cold acetone for 10 
minutes, air dried for an additional 30 minutes, and kept frozen until staining.  
A circle was drawn around the tissue section using a hydrophobic PAP pen, 1X 
PBS was added to the circle for 10 minutes, PBS was blotted off. Tissue sample 
was blocked by adding 5% BSA to tissue section for 1 hour at room temperature 
in humidified chamber or overnight at 4 degrees.   
 Tissue slides were washed with 1xPBS three times and stained with 1:50 
GL7 FITC (clone, company), 1:100 IgD Alexa Fluor 647 (clone, company), and 
1:2000 B220 Fluorochrome (clone, company) in 5% BSA at 3 hours at room 
temperature in humidified chamber or overnight at 4 degrees. Slides were then 
washed with 1xPBS three times. Mount using Prolong Gold anti-fade with Dapi 
(company). Lecia DM6000 Epi-Fluorescent microscope was used to capture 
images of whole spleens and specific germinal center sections. Leica software is 
LAS AF was used to process each image. GCs were manually counted from 







Statistical tests were performed using Prism (GraphPad) software, and p 
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Chapter 3:  






















Adenosine is an immunosuppressive purine nucleoside that promotes 
immunological tolerance, an active process that prevents the improper activation 
of autoreactive immune cells (7). Purinergic G protein-coupled receptor 
Adenosine 2a (A2aR) can act as a barrier to autoimmunity by limiting 
inflammation and negatively regulating adaptive immune responses (4). Previous 
studies using mouse models of T cell–mediated autoimmune disorders 
(12,13,14,42) have shown that A2aR signaling can restore immune homeostasis 
by promoting the induction of T cell anergy, regulatory T cell (Treg) 
differentiation, and by blocking the function of effector T cells. 
Our data from chapter 2 suggest that in vivo A2aR signaling during the 
primary response to antigen plus a strong adjuvant diverts CD4 T cells away from 
the follicular (Tfh) and Germinal Center (GC)-Tfh lineage and can reduce 
humoral immune responses (73). A similar finding was recently published by 
Abbot and colleagues (74) where a regimen of CGS treatment following 
immunization with a strong adjuvant also suppressed Tfh/GC-Tfh differentiation, 
GC B cells, and the class-switching of B cells to IgG1 plasmablasts (74).  
Although GC-Tfh cells are beneficial during the clearance of specific 
pathogens, they can also be detrimental if they malfunction and mistakenly 
provide help to pathogenic self-specific B cells. Pathological symptoms of B cell-
mediated autoimmune disorders are partially attributed to enhanced production of 
autoantibodies (39,40,45). Full penetrance of autoantibody production requires T 
cell help from GC-Tfh cells. Enhanced frequencies of GC-Tfh cells has been 
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reported in patients suffering from antibody-mediated autoimmune disorders (43, 
44). A2aRs appear to be a particularly attractive target for the treatment of B cell-
dependent autoimmune disorders such as systemic lupus erythematosus (45,69) 
and rheumatoid arthritis (RA)(43, 44) due to their ability to divert CD4 T cells 
away from a GC-Tfh lineage that may provide help to pathogenic B cells.  
To investigate whether A2aR signals could restore immune homeostasis 
during the recognition of self-antigens, we utilized a CD4 T cell transgenic mouse 
model of arthritis that relies on the recognition of a glucose-6-phosphate 
isomerase (GPI) in the context of MHC-II/I-Ag7 by arthritic GPI-specific CD4 T 
cells (KRN T cells). When KRN T cells are adoptively transferred into wild type 
B6xB6g7 (WT)F1 hosts, they become functionally unresponsive (anergic), and do 
not cause pathology (64). However, when KRN T cells transferred into a T cell 
deficient F1 host (TCRa KO) that lacks peripheral immune tolerance mechanisms 
such as regulatory T cells (Tregs), they differentiate into effector lineages that 
cause pathology (64). Studies have shown that Tfh and GC-Tfh cells contribute to 
the formation of germinal centers, autoantibody production, and disease 
manifestation in the spontaneous K/BxN mouse model of arthritis (75). In these 
studies T cell-specific deficiencies of Tfh molecules such as the chemokine 
receptor type 5 (CXCR5) and signaling lymphocytic activation molecule–
associated protein (SAP) were enough to protect mice from developing severe 
autoimmune arthritis (76). To see if activation of A2aRs can also protect against 
the development of autoimmune arthritis by diverting T cells away from a GC-
Tfh lineage, we adoptively transferred naïve KRN T cells into WT and TCRa KO 
28 
recipients. Mice were given a daily regimen of selective A2aR agonist CGS (2.5 
mg/kg i.p.) or vehicle (PBS) twice daily for the duration of the experiment.  
 
3.2 Adenosine 2a receptor signals promote immune tolerance 
KRN T cells transferred into WT mice with intact peripheral immune 
tolerance mechanisms did not develop arthritis regardless of PBS or CGS 
treatment (Fig. 8A). TCRa KO hosts that received KRN T cells and PBS 
treatment over the course of 10 days developed severe to moderate clinical scores 
(Fig. 8A) and had augmented ankle swelling (Fig. 8B). CGS treatment 
significantly reduced clinical scores (Fig. 8A) and ankle swelling in TCRa KO 
hosts (Fig 8B). Therefore, supporting previous studies that suggest A2aR signals 
can block the development of autoimmunity.  
Autoantibodies are an important contributing factor for disease 
manifestation of autoimmune arthritis (75). We observed an expansion of GPI-
specific GPI-specific plasmablasts (FSChiIgH+LhiB220lo CD38- GL7- ) in PBS 
treated TCRa KO hosts, but not in WT (PBS or CGS treated) hosts (Fig. 8C). 
CGS treatment significantly reduced GPI-specific plasmablasts in TCRa KO 
hosts compared with PBS treated mice (Fig. 8C). IgG1 is the dominant isotype 
found in arthritic mice (75). Previous work from our lab support these findings 
and have observed enhanced anti-GPI IgG1 antibody titers and GPI-specific IgG1 
class-switched plasmablasts in the secondary lymphoid organs (SLO) of arthritic 
mice (64). WT hosts had low anti-GPI IgG1 antibody titers (Fig. 1E) and only a 
modest number of GPI specific IgG1 class-switched plasmablasts compared with 
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PBS treated TCRa KO hosts (Fig. 8C, D). CGS treated TCRa KO hosts had 
significantly less anti-GPI IgG1 antibody titers (Fig. 8E) and GPI-specific IgG1 
class-switched plasmablast numbers compared to PBS treated TCRa KO mice 
(Fig. 8C, D). These data suggest that A2aR-mediated suppression of autoimmune 
arthritis may is associated with a significant reduction of anti-GPI humoral 
immune responses.  
 
3.3 A2aR signals do not promote anergy or Treg induction 
Previous studies from our lab and others have reported that Tregs are 
indispensable for peripheral immune tolerance (8, 64). A study from our lab 
reported that reconstituting T cell deficient (TCRa KO) hosts with regulatory T 
cells (Tregs) blocked autoimmune arthritis by rendering pathogenic KRN T cells 
functionally unresponsive (64). Tregs co-express high levels of cell-surface 
ectoenzymes CD39 and CD73 that break down ATP to adenosine. Previous 
studies suggest that A2aR signaling promotes tolerance by inducing anergy, Treg 
differentiation, and enhancing Treg suppression (12). In contrast to these findings, 
our data in chapter 2 suggest that A2aR signals do not promote anergy or Treg 
induction in response to foreign antigen (73), however it remained unclear if 
A2aR signals responded in a similar fashion during self-antigen recognition. To 
further examine how A2aR signals blocked autoimmune arthritis, we first 
addressed the role of A2aR signals in regulating the clonal expansion of KRN T 
cells (Fig. 8F). KRN T cells were isolated from the secondary lymphoid organs 
(SLOs) ten days after KRN adoptive T cell transfer.  A greater clonal expansion 
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of KRN T cell was seen in TCRa KO hosts (PBS and CGS treated) compared to 
WT hosts as previously reported (64) (Fig 8F). CGS treatment did not enhance 
nor reduce the expansion KRN T cells in either WT or TCRa KO hosts (Fig. 8F). 
To determine if CGS treatment protected mice from severe autoimmune 
arthritis by promoting Treg differentiation, we examined the expression of the 
master regulator/transcription factor Foxp3 (Fig. 9A). CGS did not enhance the 
expression of Foxp3, therefore it did not promote Treg induction of KRN T cells 
(Fig. 9A). To determine if CGS treatment protected mice from severe 
autoimmune arthritis by promoting T cell anergy, we examined the expression of 
surface anergy molecules CD73 (Nt5e) and FR4 (Izumo1r) (63, 64). KRN T cells 
isolated from WT hosts expressed high levels of anergy markers CD73 and FR4 
regardless of PBS or CGS treatment (Fig. 9B). Most KRN T cells from PBS 
treated TCRa KO mice had low expression of CD73 and FR4 (Fig. 9B). KRN T 
cells from CGS treated TCRa KO mice appeared to have lower CD73 and FR4 
expression compare with PBS treated TCRa KO hosts (similar to our vaccine 
study in chapter 2). We next looked at the functional unresponsive state of KRN T 
cells after CGS treatment by examining the expression of the proliferative marker 
Ki67. To our surprise, despite reduced clinical scores, KRN T cells taken from 
CGS treated TCRa KO hosts expressed higher levels of the Ki67 compared with 
PBS treated TCRa KO hosts (Fig. 9C). We next determined if KRN T cells were 
functionally unresponsive by re-stimulating them in vitro and measuring cytokine 
production. To do this we isolated KRN T cells from the SLOs of different hosts 
and re-stimulated them in vitro for 4 hours using phorbol myristate acetate (PMA) 
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and ionomycin. Production levels of TNF-a and IL-2 were elevated in KRN T 
cells isolated from both CGS and PBS treated TCRa KO hosts (Fig. 9D). 
Cytokine production between KRN T cells isolated from CGS and PBS treated 
TCRa KO hosts was unchanged (Fig. 9D). Therefore, our data suggest that A2aR 
signals do not promote anergy or Treg differentiation.  
 
3.4 A2aR signals divert arthritic KRN T cells away from a Tfh/GC-Tfh fate 
Anergic KRN T cells from WT PBS and CGS treated hosts expressed a 
CD73hi FR4hi anergic phenotype, however they remained relatively low for 
CXCR5, a chemokine receptor highly expressed on Tfh and GC-Tfh cells. In 
contrast, KRN T cells isolated from PBS treated TCRa KO mice developed a 
sizable population of CXCR5+ T cells that also expressed moderate levels of FR4 
(data not shown) and CD73 (Fig 9E). In contrast, KRN T cells from CGS treated 
TCRa KO hosts had a FR4lo CD73lo CXCR5- profile similar to what was reported 
in our vaccine study (73).  
To assess whether A2aR signals promoted tolerance by diverting CD4 T 
cells from a Tfh and GC-Tfh differentiation lineage, we looked at the expression 
of the cell surface markers PD-1 and the transcription factor Bcl-6 (31, 32). CD4 
T cells that express the highest levels of CXCR5, Bc-l6, and PD-1 have been 
characterized as GC-Tfh cells (Bcl6hi CXCR5hi) and are known to provide cognate 
help to antigen-specific B cells within germinal centers, whereas CD4 T cells 
expressing lower levels are characterized as Tfh cells (Bcl6lo CXCR5lo) and reside 
at the T cell/B cell border (66). A small frequency of KRN Tfh and GC-Tfh cells 
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were found in PBS treated WT hosts, however, CGS treatment reduced the few 
Tfh and GC Tfh cells in WT treated mice (Fig. 10A, B). A sizable number of 
KRN Tfh and GC-Tfh cells were found in the SLOs of PBS treated TCRa KO 
hosts (Fig. 10A, B). CGS treatment significantly reduced the frequency and 
number of KRN Tfh and GC-Tfh cells in CGS treated TCRa KO hosts (Fig. 10A, 
B). CGS treatment also elicited a small, but significant increase in non-Tfh KRN 
T cells (Fig 10A, B). Lineage assessment of non-Tfh cells revealed that the 
number of Th1 T-bet+ (Fig. 10C) and Th17 RORgt+ (Fig. 10D) remained 
consistent between CGS and PBS treated mice. 
Next, we examined whether our linage assessment matched cytokine 
production. A small, but significant reduction of IL-21 producing KRN T cells 
was observed in CGS treated TCRa KO hosts compared with PBS treated mice 
(Fig. 10E). IFN-g and IL-17 production was unaffected CGS treatment (Fig. 10E). 
Additionally, IL-13 and IL-5 production was assessed to determine if CGS 
treatment affected Th2 responses. CGS treatment did not affect IL-13 or IL-5 
production (data not shown).  
 
3.5 A2aR-mediated protection is T cell-dependent 
A2aR expression is highly induced on CD4 T cells following TCR ligation 
(9-11), however A2aRs can also be expressed on other cells of hematopoietic 
origin. Tfh differentiation is a multifactorial process that involves multiple cell 
types (31, 32, 66). Therefore, it was important to determine whether the effects of 
CGS were the result of direct A2aR engagement on the KRN T cells or on other 
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important cell types. Additionally, disease manifestation of autoimmune disorders 
is also multifaceted and requires not only the participation of autoreactive T cells, 
but also pathogenic B cells that secrete autoantibodies, and innate immune cells 
like neutrophils and mast cells to promote inflammatory responses (75). Figure 8 
shows that CGS treatment reduced humoral immune responses; therefore, it is 
possible that CGS-mediated protection is due to the loss of GC-Tfh specific help 
to GPI-specific B cells that promotes class-switching of B cells to 
IgG1plasmablasts. However, it is also possible that A2aR-mediated protection is 
T cell independent and acting directly on the B cells or other innate immune cells.  
To address this question, we generated KRN transgenic CD4-Cre 
Adora2af/f conditional knock-out (KO) mice lacking A2aRs only on their T 
cells.  KO KRN T cells and WT KRN T cells were transferred into TCRa KO 
recipients that lacked T cells, but globally expressed A2aRs on all other cell 
types. Each group was given a 10-day course of CGS or PBS treatment. In the 
absence of T cell-specific A2a receptors, CGS treatment failed to protect mice 
from autoimmune arthritis (Fig. 11). Recipients of KO KRN T cells with CGS 
treatment had comparable clinical scores (Fig. 11A) and ankle swelling (Fig. 
11B) to that of PBS treated recipients of KO or WT KRN T cells. 
In the absence of T cell specific A2aRs, CGS failed to reduce Bcl-6 
expression and block GC-Tfh differentiation (Fig. 12 A, B).  Likewise, CGS 
treatment failed to induce an increase in the frequency (Fig. 12A) and number of 
non-Tfh KO KRN T cell (Fig. 12B).  Lineage assessment of non-Tfh cells 
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revealed that the frequency of Th1 Tbet+ and Th17 RORgt+ KRN T cells remained 
consistent between recipients of KO KRN and WT KRN T cells (data not shown).  
To determine if A2aR-mediated reduction of humoral immune responses 
against GPI were also T cell-dependent we examined the frequency and number 
of IgG1 class-switched GPI plasmablasts in SLOs of WT and KO KRN T cell 
recipient mice treated with either PBS or CGS (Fig. 12C, D). In the absence of T 
cell specific A2aRs, CGS treatment fails to reduce the frequency (Fig. 12C) and 
number (Fig. 12D) of IgG1 class-switched GPI plasmablasts. Therefore, the 
A2aR-mediated reduction of humoral immune responses is T cell-intrinsic. 
 
3.6 Discussion 
Purinergic G protein-coupled receptor Adenosine 2a (A2aR) is thought to 
act as a barrier to autoimmunity by limiting inflammation (7, 70). Our data show 
that activation of A2aRs using a selective A2aR agonist (CGS) blocked the 
development severe autoimmune arthritis (Fig 8A, B). A2aR-meditated protection 
has been observed in other mouse models of autoimmunity (12), colitis (13), and 
graft-versus-host disease (14). However, our data suggest that A2aR-mediated 
protection was not due to induction of T cell anergy or Treg differentiation, but 
rather by diverting arthritic T cells away from a Tfh and GC-Tfh lineage that 
provides help to dangerous self-specific B cells (73).  
Pathogenic autoantibodies are an important factor that contribute to the 
development of disease (39,40,45). IgG1 is the dominant isotype found in arthritic 
mice and contributes to disease manifestation by interacting with components of 
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the alternative complement pathway that initiates potent effector function and 
chemotactic activities of mast cells and neutrophils (75). Multimerized IgG1can 
also activate FcgRIII receptors on innate immune cells that promote downstream 
effector functions (75). A2aR signals significantly reduced anti-GPI IgG1 
antibody titers and GPI-specific IgG1 class-switched plasmblasts (Fig. 8C, D). 
Our data show that CGS mediated responses are T cell dependent.  In the absence 
of T cell specific A2aRs, CGS treatment failed to block autoimmune arthritis (Fig 
11A, B), reduce GC-Tfh cells (Fig. 12 A, B), and block the differentiation of GPI-
specific IgG1 class-switched plasmablasts (Fig. 12C, D). Thus, A2aR-mediated 
immunoregulatory responses and protection from arthritis are T cell-dependent.  
Similar to our vaccine study in chapter 2, we saw a significant reduction of 
KRN Tfh and GC Tfh cells (Fig. 12A, B) and a slight increase of non-Tfh cells. 
Bcl6 is a repressor that promotes differentiation to the Tfh and GC-Tfh lineage 
fate, in part, by repressing other lineage-specific transcription factors such as Tbet 
and RORgt (31,32).  However, we did not see an increase in Th1 Tbet+ or Th17 
RORgt+  KRN T cells between CGS and PBS TCRa KO hosts (Fig. 3C-E). We 
also did not see an increase of Tregs (Foxp3+) or Th2 (GATA3+) cells in CGS 
treated mice (data not shown). Therefore, the increase of non-Tfh cells is 
comprised mainly of lineage uncommitted T cells. However, it is unclear whether 
these uncommitted T cells play any kind of functional role in restoring immune 
homeostasis.  
 A2aR activation reduces Tfh and GC-Tfh differentiation; however, 
treatment with a selective A2aR antagonist or selectively knocking-out T cell 
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specific A2aRs does not enhance Tfh or GC-Tfh cells (Fig 12 A, B). A2aR KO T 
cells also did not accelerate autoimmunity in PBS treated TCRa KO mice (Fig. 
11A, B) nor did they induce any form of arthritis in WT hosts (data not show).  It 
is possible that compensatory mechanisms make up for the loss of A2aR signals. 
A2b receptors are homologous to A2a receptors and share the same cAMP/PKA 
signaling pathway (16,17). A2b receptors are mainly expressed by dendritic cells 
and macrophages and can be expressed at low levels on lymphocytes (9,10). A2b 
receptors have a lower affinity for adenosine compared with A2a receptors (4). It 
is possible that the absence of A2a receptors may allow for available adenosine to 
bind and activate A2b receptors and that these signals compensate for the loss of 
A2aR signals. Therefore, additional studies are necessary to examine the 
relationship between A2a and A2b receptor signaling and their potential role in 
altering Tfh/GC-Tfh differentiation. 
Methotrexate and sulfasalazine are popular frontline disease-modifying 
antirheumatic drugs (DMARD) that are commonly prescribed to individuals 
suffering from systemic autoimmune disorders like Rheumatoid arthritis (RA) 
(60). The anti-inflammatory effects of these particular DMARDS are partially 
attributed to augmented extracellular adenosine levels. It has been suggested that 
these DMARDs may act through A2a receptors. Our studies support the idea that 
A2aRs can alleviate autoimmune arthritis and may be an excellent therapeutic 
target for next-generation immune targeted therapies for individuals suffering 
from antibody–mediated autoimmune disorders.  
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3.7 Materials and Methods: 
Mice 
B6 (WT) mice were purchased from Charles River Breeding Laboratories 
under a contract from the National Cancer Institute (Frederick, MD). KRN mice 
that express a TCR transgene specific for GPI/I-Ag7 were gifts from Drs. Diane 
Mathis and Christophe Benoist (Harvard Medical School, Boston, MA)(64). B6 
TCR a-/- (B6.129S2-Tcratm1Mom/J), and CD45.1+ (B6.SJL-Ptprca Pep3b/BoyJ) 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Adora2af/f 
mice containing loxP sites on either side of exon 2 of the Adora2a gene (a gift 
from Joel Linden, La Jolla Institute for Allergy and Immunology, La Jolla, CA) 
(11) were crossed with CD4-Cre mice (a gift from Michael Farrar, University of 
Minnesota, Minneapolis, MN) to generate conditional A2aR T cell knockout 
(KO) mice.  The breeding of CD45.1+ KRN, CD4-Cre Adora2af/f conditional 
knock-out KO KRN (KO), B6 x B6.g7 (WT), TCRa-/- B6xg7, and TCRa-/- B6 x 
B6.g7 mice was carried out in our own colonies. All experimental protocols were 
performed in accordance with guidelines of the University of Minnesota 
Institutional Animal Care and Use Committee and the National Institutes of 
Health. 
 
Adoptive Transfer of KRN T cells 
Prior to adoptive transfer, WT and TCRa -/- hosts were depleted of NK 
cells by administering anti-asialo GM1 Ab (Wako Chemicals USA, Richmond, 
VA) at a dose of 25 mg/mouse via i.p. injection starting at on day 0, every 5 days 
38 
for the duration of the experiment.  Donor CD45.1+ KRN spleen and lymph node 
cells were enriched for naïve CD4 T cells using a Mouse CD4 T Cell Negative 
Isolation Kit (Stem Cell) per the manufacturer’s instructions. Purified naïve KRN 
T cells were then adoptively transferred (approximately 10,000 per recipient) via 
tail vein injection. 
 
Selective A2aR agonist treatment 
Recipient were given a 10-12-day course of twice daily i.p. injection with 
the selective A2aR agonist, CGS-21680 (CGS; Tocris) 2.5 mg/kg or with vehicle 




Cell enrichment and flow cytometry 
KRN T cells were analyzed by collecting the spleen and lymph node cells 
and staining with PE-conjugated Ab to CD45.1 (A20; eBioscience). KRN T cells 
were enriched using a PE positive selection kit (STEM cell) per the 
manufacturer’s instructions. Anergy in KRN T cells was assessed by staining with 
CD73 (TY11.8) and folate receptor 4 (FR4, 12A5) as previously outlined (63, 64). 
Assessment of KRN T cell differentiation was done by surface staining enriched 
KRN T cells with CXCR5 (2G8), PD-1 (J43), CD4 (RM4-5), CD44 (IM7), as 
well as with the irrelevant cell exclusion antibodies CD11c (N418), B220 (RA3-
6B2), CD8 (53-6.7), and F4/80(BM8), and then fixed/permeabilized using a 
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fixation/permeabilization kit (eBioscience) followed by intracellular staining with 
Foxp3 (FJK-16s), Tbet (4B10), Bcl6 (K112-91), RORg (Q31-378), and Ki67 
(SoA15). To assess cytokine production KRN T cells were incubated for 3 h at 
37°C in RPMI medium 1640 + 10% FCS in the presence of 50 ng/ml PMA 
(Sigma-Aldrich, St. Louis, MO) and 1 mM ionomycin (EMD Chemicals, 
Gibbstown, NJ), in the final 2 hours KRN cells were incubated with 10 mg/ml 
brefeldin A (Sigma-Aldrich). After incubation cells were stained with the surface 
stained with CD4 (RM4-5), CD44 (IM7), as well as with the irrelevant cell 
exclusion antibodies CD11c (N418), B220 (RA3-6B2), CD8 (53-6.7), and 
F4/80(BM8). Intracellular staining was preformed using the 
fixation/permeabilization kit (eBioscience) per the manufacturer’s instructions 
and staining with IL-2 (JESS-5H4),  IFN-g (XMG1.2), anti–TNF-a (MP6-XT22), 
and IL-21 (clone). To assess GPI specific IgG1 plasmablasts, bulk lymphocytes 
were stained with B220 (RA3-6B2), GL7 (GL-7), CD38 (90), IgM (RMM-1), and 
IgD (11-26c.2a), as well as with the irrelevant cell exclusion antibodies CD11c 
(N418), CD4 (GK1.5), CD8 (53-6.7), and F4/80(BM8), and fixed/permeabilized 
using a fixation/permeabilization kit (eBioscience) and intracellular stained with 
goat anti-mouse Ig (H+L) (A11068), biotin-conjugated recombinant mouse GPI 
(kindly provided by Dr. Haochu Huang, University of Chicago, Chicago, IL) (64), 
and IgG1 (RMG1-1). All cells were analyzed using a BD LSR II flow cytometer 





Ankle swelling was measured using a Quick-Mini Series 700 comparator 
(Mitutoyo, Aurora, IL). Changes were reported as the percent change in ankle 
thickness from day 0.  Clinical scores to assess arthritis severity was also assigned 
a score from 0–3 for each paw based on the erythema/swelling as previously 
described (64). 
 
Anti-GPI IgG1 Ab measurement 
Serum was isolated from recipient mice on specified days and measured 
for anti-GPI IgG1 Abs by ELISA using recombinant mouse GPI together with 
IgG1-specific anti-mouse Ig reagents as previously described (64). 
 
Statistical analysis 
Statistical tests were performed using Prism (GraphPad) software, and p 
values were obtained using an unpaired one-tailed Student’s t-test with a 95% 
confidence interval. Mean Arthritis Clinical Index scores were compared using 
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Chapter 4:  





















Prophylactic treatment with CGS blocks the development of severe 
autoimmune arthritis, however, in a clinical setting it is unlikely that patients will 
seek medical treatment prior to developing symptoms. For this reason, we 
explored the function of A2aR activation after the early onset of autoimmune 
arthritis. We began a CGS therapeutic regiment at a time point where KRN Tfh, 
GC-Tfh T cell, and anti-GPI IgG1 antibody titers are detectable.   
 
4.2 CGS therapy blocks autoimmune arthritis disease progression  
To assess the impact of activating A2aR signals after disease 
manifestation we adoptively transferred naïve KRN T cells into TCRa KO hosts 
and waited 8 days (after early signs of disease) to administer CGS (2.5 mg/kg i.p.) 
or vehicle alone as a control (PBS) (Fig 13). We then monitored clinical scores, 
collected the KRN T cells, and IgG1 class-switched GPI plasmablasts from the 
secondary lymphoid organs (SLOs) at days 8 (zero treatments), day 10 (4 CGS 
treatments), and day 12 (8 CGS treatments) (Fig 13).  
Clinical symptoms of PBS treated hosts incrementally worsened over time 
(Fig. 14A). Activation of A2aRs significantly reduced disease severity after 4 
CGS treatments (Day 10) and remained low after 8 CGS treatments (Day 12) 
(Fig. 14 A). Clinical scores matched the severity of ankle swelling seen in CGS 
and PBS treated mice (Fig. 14B). Four CGS doses significantly blocked ankle 
swelling of both the right and left ankles (Fig. 14B). Additional CGS doses 
continued to block ankle swelling at day 12 (Fig. 14B). 
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4.3 CGS therapy reduces GPI specific GC-Tfh cells  
A previous study from our lab examined the kinetics of KRN T cell clonal 
expansion in arthritic TCRa KO hosts and demonstrated that the peak of 
expansion occurs 5 days after KRN transfer (64). A slow clonal contraction phase 
follows day 5 and a steady declined of KRN T cells is observed over time (64). 
Our data matched this observation and we see a reduction of total KRN T cells 
between days 8 and 10 (Fig. 15A). However, the rate of clonal contraction 
appears to have slowed between days 10 and 12 (Fig. 15A). A modest number of 
KRN Tfh and GC-Tfh cells was found in the secondary lymphoid organs (SLOs) 
at day 8 and continue to increase over time at days 10 and 12 (Fig 15B, C). A2aR 
activation beginning at day 8 reduced the number (Fig. 15D) and frequency (Fig. 
15C) of GC-Tfh cells after 4 doses of CGS (Day 10). The decline of KRN GC-
Tfh cell numbers continued after 8 doses of CGS at Day 12 (Fig. 15B, C). CGS 
therapy had a lesser effect on KRN Tfh cells where a small, but not significant 
reduction was observed (Fig. 15B, C). However, CGS therapy did have a small 
effect on KRN non-Tfh cells where a significant increase was observed in CGS 
treated mice (Fig. 15B, C, D). Examination of the non-Tfh cells again suggested 
that CGS treatment did not promote Treg induction nor did it enhance the number 
of Th1, Th17, or Th2 lineage cells (data not shown).  
 
4.4 CGS therapy reduces humoral immune responses   
Serum samples were collected from mice at days 8, 10, and 12 (Fig. 16A).  
Modest levels of anti-GPI IgG1 antibody titers were seen at day 8 and continued 
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to rise at days 10 and 12 in PBS treated hosts (Fig. 16A). Four CGS doses had no 
impact on anti-GPI IgG1 antibody titers (day 10); however, by 8 CGS doses (Day 
12) the anti-GPI IgG1 antibody titers was significantly less (Fig. 16A). To our 
surprise, the number of IgG1 class-switched GPI plasmablasts isolated from the 
SLOs did not match the antibody titers observed in CGS treated mice (Fig. 16B, 
C). CGS treatment did not appear to reduce the overall numbers of IgG1class-
switched GPI plasmablasts isolated from the SLOs (Fig. 16B, C).  
 
4.5 CGS therapy fails to block against autoimmune arthritis in the presence of 
high affinity autoantibodies 
 Autoantibodies are an important contributing factor for disease 
manifestation of autoimmune arthritis with IgG1 being the dominant isotype that 
initiates inflammatory responses associated with disease (39,40,45). 
Autoantibodies contribute to disease manifestation by interacting with 
components of the alternative complement pathway and FcgRIII receptors that 
initiates potent effector functions of innate immune cells (75).  
CGS therapy significantly reduced anti-GPI IgG1 antibody titers, therefore 
to determine if CGS mediated protection was due to the loss of high affinity 
antibodies we passively transferred serum from sick K/BxN mice into WT hosts 
(Fig. 17A). At the early signs of disease (day 6), we began administering CGS as 
previously described (Fig. 17A). CGS treatment failed to stop the progression of 
autoimmune arthritis in the presence of high affinity antibodies and immune 
46 
complexes specific for GPI, supporting the idea that CGS-mediated protection 
may be due, in part, to the loss of anti-GPI IgG1antibody titers (Fig. 17 B, C). 
 
4.6 Discussion 
The ultimate goal of immunotherapy is to both alleviate symptoms and 
restore immune homeostasis (7).  Therapeutic CGS treatment not only blocked 
disease progression, but also reduced the presence of dangerous 
immunomodulatory cells that contribute to disease manifestation. Enhanced 
frequencies of GC-Tfh cells has been reported in patients suffering from 
antibody-mediated autoimmune disorders (43, 44). We saw an accumulation of 
autoreactive Tfh and GC-Tfh cells between days 8-12 that correlated with 
increasing clinical scores (Fig 14 & 15).   In chapter 3, prophylactic treatment 
with CGS blocked the development of severe autoimmune arthritis by inhibiting 
KRN Tfh and GC-Tfh differentiation. We observed that eight days after KRN T 
cell were transferred into TCRa KO hosts, a modest frequency of Tfh and GC-
Tfh cells were present in secondary lymphoid organs (SLOs)of mice (Fig. 14). 
CGS therapy reduced the frequency and number of GC-Tfh cells, but not Tfh cells 
after only 4 doses of CGS (Fig. 14). However, CGS therapy did not reduce the 
overall number of KRN CD4 T cells (Fig. 14A). Instead, the significant loss of 
GC-Tfh cells appears to be compensated by an increase of non-Tfh cells (Fig. 14). 
Further examination of non-Tfh cells revealed that the CGS therapy did not 
promote anergy or Treg induction (data not shown). Nor did it enhance or reduce 
the number of Th1, Th17, or Th2 cells (data not shown). Increases were among 
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non-committed T cells. It is unclear whether these uncommitted cells play a role 
in blocking autoimmune arthritis. 
 CGS therapy reduced anti-GPI IgG1 antibody titers after 8 doses of CGS; 
however, the total frequency and number of GPI IgG1 class-switched 
plasmablasts isolated from the SLOs organs remained the same between CGS and 
PBS treated hosts (Fig 16). This was a rather perplexing observation. It is possible 
enumerating GPI-specific IgG1 plasmablasts from only the SLOs may not 
accurately compute the total number of GPI-specific IgG1 antibody-secreting 
cells (ASC) in the host. Studies have shown that ectopic germinal centers can 
form in the joints of collagen-induced arthritic mice and have been found in the 
joints of affected patients (77). It is possible that some GPI-specific ASCs may 
reside in non-lymphoid organs; therefore, observations made in the SLOs may not 
capture the difference between CGS and PBS treated hosts.  
Although discrepancies between anti-GPI IgG1 antibody titers and number 
of GPI IgG1 class-switched plasmablasts were observed, it was clear that CGS 
protection worked, in part, by reducing the levels of dangerous high affinity IgG1 
antibodies responding to GPI. CGS therapy failed to provide any protection 
against autoimmune arthritis in the presence of transferred high affinity anti-GPI 
autoantibodies (Fig. 17), thus supporting the idea that significant reduction of 
anti-GPI IgG1 antibody titers contributes to CGS-mediated protection against 
disease progression. However, it is unclear whether the loss of GC-Tfh cells is 
important to the loss of pathogenic autoantibodies. It is possible that the loss of 
GC-Tfh disrupts the GC microstructure that is needed for GPI-specific B cells to 
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undergo extensive class-switching and affinity maturation. Additional studies are 
needed to examine how CGS therapy alters GC structures.  
The therapeutic benefits of adenosine in autoimmune disorders have been 
previously reported in patients treated with methotrexate (MTX), a popular 
DMARD commonly prescribed to individuals suffering from systemic 
autoimmune disorders like rheumatoid arthritis (RA) (48). The anti-inflammatory 
effects of MTX are attributed to augmented levels of extracellular adenosine (60). 
Therapeutic CGS treatment after the development of mild arthritis blocked 
disease progression, reduced GC-Tfh cells, and anti-GPI IgG antibodies titers. 
Therefore, our data suggest that A2aR downstream signaling may serve to limit 
dangerous immune responses that contribute to autoimmune disease 
manifestations. It is of great interest to identify the factors downstream of 
adenosine that alleviate symptoms of arthritis. Identify potential therapeutic 
targets within the A2aR pathway may one day pioneer better immunotherapies for 












4.7 Materials and Methods 
Mice 
B6 (WT) mice were purchased from Charles River Breeding Laboratories 
under a contract from the National Cancer Institute (Frederick, MD). KRN mice 
that express a TCR transgene specific for GPI/I-Ag7 were gifts from Drs. Diane 
Mathis and Christophe Benoist (Harvard Medical School, Boston, MA)(64). B6 
TCR a-/- (B6.129S2-Tcratm1Mom/J), and CD45.1+ (B6.SJL-Ptprca Pep3b/BoyJ) 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME).  The 
breeding of CD45.1+ KRN, B6 x B6.g7 (WT), TCRa-/- B6xg7, and TCRa-/- B6 
x B6.g7 mice was carried out in our own colonies. All experimental protocols 
were performed in accordance with guidelines of the University of Minnesota 
Institutional Animal Care and Use Committee and the National Institutes of 
Health. 
 
Adoptive Transfer of KRN T cells 
Donor CD45.1+ KRN spleen and lymph node cells were enriched for naïve 
CD4 T cells using a Mouse CD4+ T Cell Negative Isolation Kit (Stem Cell) per 
the manufacturer’s instructions. Purified naïve KRN T cells (104) were then 






Selective A2aR agonist treatment 
Recipient were given a twice daily i.p. injection with the selective A2aR 
agonist, CGS-21680 (CGS; Tocris) 2.5 mg/kg or with vehicle alone (PBS) 
starting at day 8 post transfer (12, 73). 
 
Serum Transfer 
Serum from K/BxN mice was a gift from Dr. Bryce Binstadt.  Age-
matched B6 x B6.g7 (WT) mice were injected with pooled serum (200 µl, i.p.) on 
days 0 and 2. Clinical scores were collected every day. Therapy was administered 
at day 6. Mice were sacrificed on day 12. 
 
Cell enrichment and flow cytometry 
KRN T cells were analyzed by collecting the spleen and lymph node cells 
and staining with PE-conjugated Ab to CD45.1 (A20; eBioscience). KRN T cells 
were enriched using a PE positive selection kit (STEM cell) per the 
manufacturer’s instructions. Anergy in KRN T cells was assessed by staining with 
CD73 (TY11.8) and folate receptor 4 (FR4, 12A5) as previously outlined (63, 64). 
Assessment of KRN T cell differentiation was done by surface staining enriched 
KRN T cells with CXCR5 (2G8), PD-1 (J43), CD4 (RM4-5), CD44 (IM7), as 
well as with the irrelevant cell exclusion antibodies CD11c (N418), B220 (RA3-
6B2), CD8 (53-6.7), and F4/80(BM8), and then fixed/permeabilized using a 
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fixation/permeabilization kit (eBioscience) followed by intracellular staining with 
Foxp3 (FJK-16s), Tbet (4B10), Bcl6 (K112-91), RORg (Q31-378), and Ki67 
(SoA15). To assess cytokine production KRN T cells were incubated for 3 h at 
37°C in RPMI medium 1640 + 10% FCS in the presence of 50 ng/ml PMA 
(Sigma-Aldrich, St. Louis, MO) and 1 mM ionomycin (EMD Chemicals, 
Gibbstown, NJ), in the final 2 hours KRN cells were incubated with 10 mg/ml 
brefeldin A (Sigma-Aldrich). After incubation cells were stained with the surface 
stained with CD4 (RM4-5), CD44 (IM7), as well as with the irrelevant cell 
exclusion antibodies CD11c (N418), B220 (RA3-6B2), CD8 (53-6.7), and 
F4/80(BM8). Intracellular staining was preformed using the 
fixation/permeabilization kit (eBioscience) per the manufacturer’s instructions 
and staining with IL-2 (JESS-5H4),  IFN-g (XMG1.2), anti–TNF-a (MP6-XT22), 
and IL-21 (clone). To assess GPI specific IgG1 plasmablasts, bulk lymphocytes 
were stained with B220 (RA3-6B2), GL7 (GL-7), CD38 (90), IgM (RMM-1), and 
IgD (11-26c.2a), as well as with the irrelevant cell exclusion antibodies CD11c 
(N418), CD4 (GK1.5), CD8 (53-6.7), and F4/80(BM8), and fixed/permeabilized 
using a fixation/permeabilization kit (eBioscience) and intracellular stained with 
goat anti-mouse Ig (H+L) (A11068), biotin-conjugated recombinant mouse GPI 
(kindly provided by Dr. Haochu Huang, University of Chicago, Chicago, IL) (64), 
and IgG1 (RMG1-1). All cells were analyzed using a BD LSR II flow cytometer 




Ankle swelling was measured using a Quick-Mini Series 700 comparator 
(Mitutoyo, Aurora, IL). Changes were reported as the percent change in ankle 
thickness from day 0.  Clinical scores to assess arthritis severity was also assigned 
a score from 0–3 for each paw based on the erythema/swelling as previously 
described (64). 
 
Anti-GPI IgG1 Ab measurement 
Serum was isolated from recipient mice on specified days and measured 
for anti-GPI IgG1 Abs by ELISA using recombinant mouse GPI together with 
IgG1-specific anti-mouse Ig reagents. 
 
Statistical analysis 
Statistical tests were performed using Prism (GraphPad) software, and p 
values were obtained using an unpaired one-tailed Student’s t-test with a 95% 
confidence interval. Mean Arthritis Clinical Index scores were compared using 
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The immune system is a complex circuitry of cells designed to detect and 
eliminate potential threats from foreign invaders while simultaneously 
suppressing inappropriate immune responses against self-tissues. The ultimate 
goal of immunotherapies is to manipulate specific components of the immune 
system that can resolve a loss of immune homeostasis often seen in patients 
suffering from cancer, autoimmune disorders, or chronic infections (7). 
Immunotherapy targets are often cellular and molecular components that fine-tune 
innate and adaptive immune responses toward a desired direction (7). 
Helper CD4 T cells are critical regulators of adaptive immune responses. 
CD4 T cells carry out a broad-spectrum of effector functions uniquely suited to 
eliminate certain pathogens by activating various immune cells such as 
macrophages, cytotoxic CD8 T cells, and B cells (36). Identifying the factors that 
fine-tune CD4 T cell responses may be instrumental in the development of 
immune-targeted therapies and new vaccine approaches (67, 68).  My thesis work 
has uncovered a novel role for purinergic Adenosine 2a receptor (A2a) in altering 
CD4 T cell responses. 
Our lab was among the first to show that A2aR signals can inhibit the 
differentiation of germinal center T follicular helper cells (GC Tfh), a CD4 T cell 
subset that promotes the propagation, differentiation, and class-switching of B 
cells (73). The loss of GC-Tfh cells resulted in a reduction of antigen-specific 
humoral immune responses. However, A2aR signals did not reduce the 
proliferation or expansion of CD4 T cells, instead a slight shift toward another 
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lineage, Th17, was observed (73). Targeting A2aRs could be beneficial during 
mucosal infections where Th17 cells are required for pathogen clearance or 
during antibody-mediated autoimmune disorders where a reduction of harmful 
GC-Tfh cells may alleviate the severity of disease (36).  
Although CD4 T cells are essential for immune homeostasis, they can at 
times malfunction, confuse self-antigens for foreign invaders, and mount 
inappropriate responses against self-tissues (46). Autoimmune disorders affect 
over 50 million individuals in the United States alone (47). Pathological 
symptoms of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) 
are partially attributed to the enhanced production of autoantibodies (39,40,45). 
Full penetrance of autoantibody production requires CD4 T cell help from GC-
Tfh cells. Enhanced frequency of GC-Tfh cells has been reported in patients 
suffering from antibody-mediated autoimmune disorders (43, 44). Studies have 
shown a tight correlation between the frequency of GC-Tfh cells and the onset of 
disease (43, 44). Our data demonstrates that A2aR signals reduced the presence of 
pathogenic Tfh/GC-Tfh cells, humoral immune responses against self-antigens, 
and blocked the development of autoimmune arthritis. Similar to our vaccine 
studies, our data suggests that A2aR-mediated responses and protection against 
arthritis are T cell-dependent.  
Prophylactic treatment with CGS blocks the development of severe 
autoimmune arthritis, however, in a clinical setting it is unlikely that patients will 
seek medical treatment before developing symptoms. For this reason, we explored 
the function of A2aR activation after the early onset of disease. Therapeutic CGS 
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treatment of mice after developing mild arthritis blocked further disease 
progression and reduced pathogenic GC-Tfh cells, and harmful anti-GPI IgG1 
autoantibody titers. Therefore, our data suggest that A2aR downstream signaling 
may serve to limit dangerous GC-Tfh cell effectors that contribute to autoimmune 
disease manifestations.  
Understanding the mechanisms that promote and repress GC-Tfh 
differentiation could identify future therapeutic targets. The therapeutic benefits 
of adenosine in autoimmune disorders have been previously reported in patients 
treated with Methotrexate (MTX), a popular disease-modifying antirheumatic 
drug (DMARD) commonly prescribed to individuals suffering from systemic 
autoimmune disorders like RA (48). The anti-inflammatory effects of MTX are 
attributed to augmented levels of extracellular adenosine (60). My thesis research 
unearthed a potential T cell specific therapeutic target that may be a key regulator 
of adenosine-mediated therapies. Identifying potential targets within the A2aR 
pathway may one day pioneer better immunotherapies for individuals suffering 









Illustrations and Figures 
 
Figure 1: A2aR signaling pathway. (1) A2aR ligation promotes the 
accumulation of intracellular second messenger cAMP (2) that bind to the 
regulatory subunits of the Protein Kinase A (PKA) complex that then (3) 
releases the catalytic PKA subunits. (4) PKA can enter the nucleus and 
phosphorylate the Serine 133 position of various molecules including the 
transcription factor CREB that is often positioned at promoter site of 
various adenosine-mediated genes. Phosphorylation can recruit additional 
transcription factors to this site to either promote or repress the 
























Figure 2: A2aR signals promote T cell tolerance. Ligation of A2a 
receptors by adenosine or selective agonists can promote anergy, 
Treg induction, enhance Treg suppression/proliferation, and reduce 




























Figure 3. A2aR signaling using the selective agonist CGS-21680 does 
not promote anergy or Treg induction during primary immunization. 
B6 mice were immunized with 2W1S-PE and subsequently given a 7d 
treatment course of the selective A2aR agonist CGS 2.5 mg/kg or 
vehicle alone (PBS). (A) The frequency and number of spleen and LN 
2W1S:I-Ab-specific CD4 T cells (with naive untreated mice shown for 
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reference). (B) Foxp3+ Tregs within the 2W1S: I-Ab-specific CD4 T 
cell compartment. (C) CD73+ FR4+ anergic-phenotype cells within the 
conventional Foxp3– 2W1S:I-Ab-specific CD4 T cell population. (D) 
Ki67 expression in conventional Foxp3– 2W1S: I-Ab-specific CD4 T 
cells 7d after 2W1S-PE immunization in the presence of CGS (2W1S 
peptide/CGS) or vehicle alone (2W1S peptide/PBS) (with endogenous 
naive polyclonal CD44lo CD4 T cells shown as a control). Data are 
representative from three independent experiments (n = 8-9 mice per 









Figure 4. A2aR activation reduces Tfh and GC-Tfh differentiation. 2W1S:I-Ab 
tetramer-binding T cells were recovered from the spleen and LNs of 2W1S-PE 
immunized WT B6 mice after 7d of treatment with either CGS or vehicle alone 
(PBS). (A) FR4 and CXCR5, (B) CD73 and CXCR5, (C) PD-1 and CXCR5, 
and (D) Bcl6 and CXCR5 staining in 2W1S:I-Ab-specific CD4 T cells from 
CGS- or PBS-treated immunized mice. (E) Aggregate numbers of Bcl-6hi 
CXCR5hi GC-Tfh, Bcl-6lo CXCR5lo Tfh, and Bcl-6– CXCR5– non-Tfh cells 
that bind the 2W1S:I-Ab tetramer.  Data are representative of three independent 






Figure 5. A2aR inhibition of GC-Tfh differentiation is T cell intrinsic. 
2W1S: I-Ab tetramer-bound CD4 T cells were enriched from spleen and 
LNs of CD4-Cre Adora2af/f conditional knock-out (KO) mice as well as 
non-Cre expressing WT littermates after 2W1S-PE immunization and a 7d 
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course of either CGS or PBS treatment. (A, B) Frequency (A) and number 
(B) of 2W1S-specific CD44hi Foxp3– CD4 T cell subsets: Bcl6hi CXCR5hi 
GC-Tfh, Bcl6lo CXCR5lo Tfh, and Bcl-6– CXCR5– non-Tfh cells. (C, D) 
Frequency (C) and number (D) of Th17 (RORgt + Tbet–) and Th1 (RORgt 
– Tbet+) lineage cells within the non-Tfh fraction of 2W1S:I-Ab tetramer-
binding CD4 T cells. (E) 2W1S-specific Foxp3+ Treg numbers. Data are 
representative of three independent experiments (n = 8-9). *P < 0.05, **P 








Figure 6. T cell A2aR activation reduces GC B cell immunity. PE-specific B 
cells were enriched from the spleen and LNs of 2W1S-PE primed WT or CD4-
Cre Adora2af/f conditional knock-out (KO) mice given a 7d course of CGS or 
the PBS vehicle alone.  (A) Gating strategy to identify PE-specific B220+ total 
B cells (left column), B220intermediate intracellular Ig (H+L)hi plasma cells 
(middle column), as well as intracellular Ig (H+L)intermediate CD38– GL7+ GC B 
cells (right column) in control untreated (upper row), 2W1S-PE immunized 
and PBS-treated (middle row), and 2W1S-PE immunized and CGS-treated 
(lower row) WT mice. (B) Representative KO mice treated as in (A). (C) 
Absolute numbers of total PE-specific B cells in WT and KO mice treated as in 
(A) and (B), with untreated mice shown as a control. (D) Absolute numbers and 
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frequency of PE-specific polyclonal CD38– GL7+ GC B cells in immunized 
WT and KO mice treated as in (A) and (B). Data are representative of three 






















Figure 7. T cell A2aR activation reduces the quantity of Germinal Center. 
Tissue slides of spleens from 2W1S-PE primed WT or CD4-Cre Adora2af/f 
conditional knock-out (KO) mice given a 7d course of CGS or the PBS 
vehicle alone.  (A) Image of a whole spleen from a 2W1S-PE primed WT 
mouse given a 7d course of PBS. Middle panels are focused on a single 
germinal center from the spleen of an immunized WT mouse given PBS. 
Each panel shows four individual staining fluorchromes for Dapi, IgD, GL7, 
and B220 that help distinguish GCs. The bottom panel overlaps the IgD, 
GL7 to clearly distinguish GCs, it also overlaps GL7 and B220 to show that 
cells in the GC complex were true B cells. Finally, the bottom right panel 
shows the overlap of all three fluorchromes that include Dapi to show the 
general requirements to be considered a GC. (B) based on the criteria from 
figure A, we manually counted the number of GC present in unimmunized, 
immunized, CGS or PBS treated WT and KO mice. Data are representative 




Figure 8: A2aR signals block autoimmune arthritis. Naïve CD45.1+ KRN T cells 
(104) were adoptively transferred into WT and TCRa KO hosts. After 24 hours, 
mice were injected (i.p.) twice daily with a selective A2aR agonist CGS (2.5 
mg/kg) or vehicle alone (PBS) for the duration of the experiment (10 days). (A) 
Clinical disease scores taken at day 10 (left) and mean percent changes of ankle 
swelling/size (mm) over the duration of the experiment (right). (B) Bulk B cells 
were stained for intracellular Ig H+L chain accumulation and GPI-binding 
capacity to examine GPI-specific plasmablasts (C) B220intermediate intracellular Ig 
(H+L) hi GL7- CD38-IgG1+GPI specific plasmablasts were enumerated. (D) Anti-
GPI IgG1 titers measured from serum of mice at day 10 via ELISA. (E) Total 
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number of CD45.1+ KRN T cells isolated from the spleen and lymph nodes of 
WT and TCRa KO (CGS and PBS treated hosts) were enumerated. Data are 
representative of three-five independent experiments (n = 6-17). *P < 0.05, **P < 





















Figure 9: A2aR signaling using the selective agonist CGS-21680 does not 
promote anergy or Treg induction. Naïve CD45.1+ KRN T cells (104) were 
adoptively transferred into WT and TCRa KO hosts. After 24 hours, mice were 
injected (i.p.) twice daily with selective A2aR agonist CGS (2.5 mg/kg) or 
vehicle alone (PBS) for the duration of the experiment (10 days). KRN T cells 
were isolated from the spleen and lymph nodes of PBS and CGS treated WT 
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and TCRa KO hosts at day 10. (A) The frequency of KRN Foxp3+ Tregs. (B) 
CD73+ FR4+ anergic-phenotype cells within the conventional Foxp3– KRN T 
cell population. (C) Ki67 expression within conventional Foxp3– KRN T cells. 
(D) KRN T cell production of IL-2 and TNF-a after PMA/ionomycin re-
stimulation. (E) CD73+ and CXCR5+ KRN T cells. Data are representative from 
three independent experiments (n = 5-10 mice per group). *P < 0.05, **P < 

































Figure 10: A2aR activation reduces Tfh and GC-Tfh differentiation. KRN T 
cells were isolated from the spleen and lymph nodes of PBS and CGS treated 
WT and TCRa KO hosts at day 10. (A) Bcl6 and CXCR5 staining of KRN T 
cells from CGS- or PBS-treated hosts. (B) Aggregate numbers of Bcl-6hi 
CXCR5hi (GC-Tfh), Bcl-6lo CXCR5lo (Tfh), and Bcl-6– CXCR5– (non-Tfh) 
KRN T cells. (C) Number Th1 (Tbet+) and (D) Th17 (RORg +) lineage cells 
within the non-Tfh fraction of KRN T cells. (E) KRN T cell production of IL-
73 
21, IFN-g, and IL-17 after PMA/ionomycin re-stimulation. Data are 
representative of three-four independent experiments (n = 4-12 mice). *P < 




















Figure 11: CGS-mediated protection is T cell-dependent. Naïve CD45.1 
KRN+ T cells (104) were enriched from spleen and LNs of KRN CD4-Cre 
Adora2af/f conditional knock-out (KO) mice and (WT) KRN mice. After 
24 hours, mice were injected (i.p.) twice daily with selective A2aR agonist 
CGS ( 2.5 mg/kg) or vehicle alone (PBS) for the duration of the 
experiment (10 days). (A) Mean clinical disease scores over time and (B) 
percent change of ankle swelling/size (mm) over the duration of the 
experiment. Data are representative of three-four independent experiments 
(n = 4-12 mice). *P < 0.05, **P < 0.01, and ***P < 0.001 
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Figure 12: A2aR inhibition of GC-Tfh differentiation and humoral immune 
responses are T cell dependent.  Naïve KRN CD4-Cre Adora2af/f conditional 
knock-out (KO) T cells (104) and WT KRN T cells were transferred into 
TCRa KO hosts. After 24 hours, mice were injected (i.p.) twice daily with 
selective A2aR agonist CGS (2.5 mg/kg) or vehicle alone (PBS) for the 
duration of the experiment (10 days). (A, B) Frequency (A) and number (B) 
of KRN CD44hi Foxp3– CD4 T cell subsets: Bcl6hi CXCR5hi (GC-Tfh), 
Bcl6lo CXCR5lo (Tfh), and Bcl-6– CXCR5– (non-Tfh cells). (C) Frequency 
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and number (D) of  B220intermediate intracellular Ig (H+L)hi GL7- CD38-
IgG1+GPI specific plasmablasts. Data are representative of three independent 
























Figure 13: Experimental set up for CGS therapy. Naïve CD45.1+ 
KRN T cells (104) were adoptively transferred into WT and TCRa KO 
hosts. After 8 days, mice were injected (i.p.) twice daily with selective 
A2aR agonist CGS (2.5 mg/kg) or vehicle alone (PBS) for the duration 
of the experiment (12 days). Serum from blood samples and KRN T 
cells from the spleen and lymph nodes of PBS and CGS treated WT 















 Figure 14: Activation of A2aRs blocks progression of autoimmune 
arthritis. (A) Clinical disease scores observed at days 8, 10, and 12. (B) 
Percent change of ankle swelling/size (mm) from day 8. Data are 
representative of three-four independent experiments (n = 4-12 mice). *P 












Figure 15: CGS therapy reduces KRN GC-Tfh cells. KRN T cells were 
isolated from the spleen and lymph nodes of PBS and CGS treated TCRa 
80 
KO hosts at days 8, 10, and 12. (A) The total number of CD45.1+ KRN T 
cells isolated from the spleen and lymph nodes of CGS or PBS TCRa KO 
hosts. (B) Bcl6 and CXCR5 staining in KRN T cells from isolated from 
CGS- or PBS-treated mice. (C) Percent and (D) number of Bcl-6hi 
CXCR5hi (GC-Tfh), Bcl-6lo CXCR5lo (Tfh), and Bcl-6– CXCR5– (non-
Tfh) KRN T cells isolated at days 8, 10, and 12. Frequency of non-Tfh (E) 
Th1 Tbet+ and (F) Th17 RORgt+. Data are representative of three 
independent experiments (n = 8-12 mice). *P < 0.05, **P < 0.01, and 
















Figure 16: A2aR activation reduced anti-GPI IgG1 antibody titers, but 
not GPI-specific IgG1 class-switched plasmablasts.  Serum from CGS and 
PBS treated mice at days 8, 10, and 12 was also collected. (A) Anti-GPI 
IgG1 titers measured from the serum of mice at day 8, 10, and 12 via 
ELISA. Bulk B cells from the spleen and lymph nodes of CGS and PBS 
treated mice at days 8, 10, and 12 were isolated, stained, and examined (B) 
Frequency and (C) number of B220intermediate intracellular Ig (H+L) hi GL7- 
CD38-IgG1+GPI specific plasmablasts from the spleen and lymph nodes 
of CGS and PBS treated mice at days 8, 10, and 12. Data are 
representative of three independent experiments (n = 4-7). *P < 0.05, **P 




Figure 17: CGS therapy fails to stop disease progression in the 
presence of high affinity antibodies. Serum collected from arthritic 
K/BxN mice was i.p. injected into WT mice at Days 0 and 2. Six days 
after serum transfer mice were injected (i.p.) twice daily with selective 
A2aR agonist CGS (2.5 mg/kg) or vehicle alone (PBS) for the duration 
of the experiment (12 days). (A) Mean clinical disease scores observed 
at days 8, 10, and 12. (B) Mean percent change of ankle swelling/size 
(mm). Data are representative of three independent experiments (n = 
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